mProX™ Human RPS6KA5 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RPS6KA5, also known as ribosomal protein S6 kinase A5, has been implicated in various biological processes and diseases. In the context of male infertility, RPS6KA5 has been identified as one of the genes potentially responsible for disturbed spermatogenesis and nonobstructive azoospermia (NOA). Activation of the ESX1 gene, including RPS6KA5, using CRISPRa technology in human germ cells showed significantly higher expression levels of RPS6KA5 in modified cells compared to wild-type cells, indicating its potential role in male infertility. In the field of placental function and metabolic analysis, RPS6KA5 was found to be differentially expressed in hyperglycemic-exposed BeWo trophoblast cells. It was also identified as one of the potential prognostic markers in esophageal adenocarcinoma, where low expression of RPS6KA5 was associated with increased overall survival. Additionally, RPS6KA5 methylation was found to be a predictor of response to treatment in adolescent patients with major depressive disorder. Finally, in colorectal cancer, RPS6KA5 was identified as one of the parental genes of m6A modified circRNAs and showed potential prognostic value for CRC patients. These findings suggest that RPS6KA5 may have diverse roles and implications in male infertility, placental function, esophageal adenocarcinoma, major depressive disorder, and colorectal cancer.